Pazopanib-votrient (200 mg, 400 mg)

GSK PHARMACEUTICALS .(INDIA)

“Pazopanib” is the Drug / Molecule content in “Votrient”.  Votrient is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR).Pazopanib blocks a number of proteins. It stops cancer cells forming blood vessels in order to grow.

Indication

Votrient is indicated for the treatment of patients with advanced renal cell carcinoma (RCC) & soft tissue sarcoma (STS) who have received prior chemotherapy.

Note

Precaution

  • Votrient is a prescription drug and should be used under proper medical guidance and advice.
  • Monitor serum liver tests before initiation of treatment with Votrient
  • Blood pressure should be well controlled prior to initiating Votrient.
  • Votrient can cause fetal harm when administered to a pregnant woman.